Residential Radon and Small Cell Lung Cancer. Final Results of the Small Cell Study.


Journal

Archivos de bronconeumologia
ISSN: 1579-2129
Titre abrégé: Arch Bronconeumol
Pays: Spain
ID NLM: 0354720

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 03 12 2020
revised: 06 01 2021
accepted: 26 01 2021
pubmed: 22 3 2022
medline: 7 7 2022
entrez: 21 3 2022
Statut: ppublish

Résumé

Residential radon is considered the second cause of lung cancer and the first in never smokers. Nevertheless, there is little information regarding the association between elevated radon levels and small cell lung cancer (SCLC). We aimed to assess the effect of residential radon exposure on the risk of SCLC in general population through a multicentric case-control study. A multicentric hospital-based case-control study was designed including 9 hospitals from Spain and Portugal, mostly including radon-prone areas. Indoor radon was measured using Solid State Nuclear Track Detectors at the Galician Radon Laboratory. A total of 375 cases and 902 controls were included, with 24.5% of cases being women. The median number of years living in the measured dwelling was higher than 25 years for both cases and controls. There was a statistically significant association for those exposed to concentrations higher than the EPA action level of 148Bq/m Radon exposure seems to increase the risk of small cell lung cancer with a linear dose-response pattern. Tobacco consumption may also produce an important effect modification for radon exposure.

Identifiants

pubmed: 35312555
pii: S0300-2896(21)00052-1
doi: 10.1016/j.arbres.2021.01.027
pii:
doi:

Substances chimiques

Radon Q74S4N8N1G

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

542-546

Informations de copyright

Copyright © 2021 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

Ángeles Rodríguez-Martínez (Á)

Service of Medical Oncology, University Hospital Complex of Pontevedra, Spain; Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain.

Alberto Ruano-Ravina (A)

Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública, CIBERESP), Spain; Instituto de Investigaciones Sanitarias de Santiago de Compostela (IDIS), Spain. Electronic address: alberto.ruano@usc.es.

María Torres-Durán (M)

Service of Neumology, University Hospital Complex of Vigo, Spain.

Mariano Provencio (M)

Service of Medical Oncology, Puerta del Hierro University Hospital of Madrid, Spain.

Isaura Parente-Lamelas (I)

Service of Neumology, University Hospital Complex of Ourense, Spain.

Iria Vidal-García (I)

Service of Neumology, University Hospital Complex of A Coruña, Spain.

Cristina Martínez (C)

National Institute of Silicosis, University Hospital of Asturias, Oviedo, Spain.

Jesús Hernández-Hernández (J)

Service of Neumology, University Hospital of Ávila, Spain.

Ihab Abdulkader-Nallib (I)

Service of Pathological Anatomy, University Complex of Santiago de Compostela, Spain.

Olalla Castro-Añón (O)

Service of Neumology, Universitary Hospital Complex of Lugo, Spain.

Leonor Varela-Lema (L)

Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública, CIBERESP), Spain; Instituto de Investigaciones Sanitarias de Santiago de Compostela (IDIS), Spain.

María Piñeiro-Lamas (M)

Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública, CIBERESP), Spain.

Paula Sales Fidalgo (PS)

Centro Hospitalar do Porto, Oncology Service, Porto, Portugal.

Alberto Fernández-Villar (A)

Service of Neumology, University Hospital Complex of Vigo, Spain.

Juan Barros-Dios (J)

Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública, CIBERESP), Spain; Service of Preventive Medicine, University Complex of Santiago de Compostela, Spain.

Mónica Pérez-Ríos (M)

Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública, CIBERESP), Spain; Instituto de Investigaciones Sanitarias de Santiago de Compostela (IDIS), Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH